UK Warns on Ibuprofen Kidney Risks
Analysis based on 17 articles · First reported Mar 12, 2026 · Last updated Mar 12, 2026
The warnings about NSAIDs like Ibuprofen could lead to a decrease in their sales and an increase in demand for alternative pain relief medications such as Paracetamol. This shift could impact pharmaceutical companies producing these drugs and potentially increase healthcare costs related to kidney disease management for entities like the United Kingdom===National Health Service.
Medical experts from Elizabeth Ward (British campaigner) and the National Pharmacy Association have issued a public health warning regarding the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as Ibuprofen, Naproxen, and Diclofenac. These drugs are cautioned for their potential to increase blood pressure and damage kidney blood vessels, particularly in individuals with pre-existing conditions like diabetes or high blood pressure. Approximately 7.2 million people in the United Kingdom are living with some form of chronic kidney disease, with an estimated one million undiagnosed. Olivier Picard, chair of the National Pharmacy Association, and Fiona Loud, policy director at Elizabeth Ward (British campaigner), emphasize the importance of patient awareness, considering alternative medications like Paracetamol, and consulting pharmacists for advice. The United Kingdom===National Health Service also advises taking the smallest effective dose of Ibuprofen for the shortest duration. The event highlights the growing concern over kidney disease, which has seen increasing death rates globally and poses significant financial burdens on healthcare systems.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard